PE20080405A1 - COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb - Google Patents

COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb

Info

Publication number
PE20080405A1
PE20080405A1 PE2007000948A PE2007000948A PE20080405A1 PE 20080405 A1 PE20080405 A1 PE 20080405A1 PE 2007000948 A PE2007000948 A PE 2007000948A PE 2007000948 A PE2007000948 A PE 2007000948A PE 20080405 A1 PE20080405 A1 PE 20080405A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
itpkb
inhibitors
compounds
Prior art date
Application number
PE2007000948A
Other languages
English (en)
Inventor
Shifeng Pan
Yi Liu
Yun Xie
Dai Cheng
Yonggin Wan
Dong Han
Yang Yang
Wenqi Gao
Jiqing Jiang
Badry Bursulaya
Philip Chamberlain
Donald S Karanewsky
Xia Wang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20080405A1 publication Critical patent/PE20080405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 0-3; m ES 0-3; A PUEDE TENER HASTA 3 GRUPOS SELECCIONADOS A PATIR DE -CR1=, -CR2=, -CR3=, -CR4=, Y -CR5=REEMPLAZADOS CON N; R1, R2, R3, R4 Y R5 SON CADA UNO H, HIDROXILO, HALOGENO, CIANO, ENTRE OTROS; R6 Y R7 SON CADA UNO H, ALQUILO C1-C3, CICLOALQUILO C3C7; R8 ES ALQUILO C1-C6, ALQUILO C1-C3 SUSTITUIDO POR HALOGENO, ALCOXILO C1-C6, ENTRE OTROS; R9 ES ARILO C6-C10, HETEROARILO C1-C10, ENTRE OTROS; R10 ES H, ALQUILO C1-C6, ENTRE OTROS; Y y Z SON CADA UNO N, CR20; R20 ES H, ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 4-{4-[4-(5-TRIFLUORO-METIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL-METIL]-1H-PIRAZOL-3-IL}- BENZONITRILO; 4-{4-[3-METIL-4-(5-TRIFLUORO-METIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL-METIL]-1H-PIRAZOL-3-IL}-FENIL-ESTER DEL ACIDO METIL-CARBAMICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON INHIBIDORES DE LA ACTIVIDAD DE CINASA DE LA MOLECULA DE ITPKb, UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES
PE2007000948A 2006-07-21 2007-07-20 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb PE20080405A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83268106P 2006-07-21 2006-07-21
US89387407P 2007-03-08 2007-03-08

Publications (1)

Publication Number Publication Date
PE20080405A1 true PE20080405A1 (es) 2008-06-18

Family

ID=38727512

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000948A PE20080405A1 (es) 2006-07-21 2007-07-20 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb

Country Status (14)

Country Link
US (1) US20090306039A1 (es)
EP (1) EP2057124A2 (es)
JP (1) JP2009544626A (es)
KR (1) KR20090029274A (es)
AR (1) AR062011A1 (es)
AU (1) AU2007275049B2 (es)
BR (1) BRPI0714440A2 (es)
CA (1) CA2656715A1 (es)
CL (1) CL2007002123A1 (es)
MX (1) MX2009000771A (es)
PE (1) PE20080405A1 (es)
RU (1) RU2425826C2 (es)
TW (1) TW200817375A (es)
WO (1) WO2008011611A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713957A2 (pt) * 2006-07-04 2013-04-02 Astrazeneca Ab composto, composiÇço farmacÊutica, uso de um composto, e, mÉtodo de tratamento de um distérbio de agregaÇço plaquetÁria
CN101743243A (zh) 2007-06-15 2010-06-16 Irm责任有限公司 作为itpkb抑制剂的化合物和组合物
EA201001586A1 (ru) * 2008-04-04 2011-06-30 Айрм Ллк Соединения и композиции в качестве ингибиторов itpkb
US8853202B2 (en) 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
KR101701367B1 (ko) * 2008-11-04 2017-02-02 케모센트릭스, 인크. Ｃｘｃｒ７의 모듈레이터
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
EP2925745B1 (en) 2012-11-29 2018-04-04 ChemoCentryx, Inc. Cxcr7 antagonists
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
MX361136B (es) 2013-01-23 2018-11-28 Astrazeneca Ab Compuestos quimicos.
RU2709482C1 (ru) 2013-12-20 2019-12-18 Эстеве Фармасьютикалз, С.А. Производные пиперазина, характеризующиеся мультимодальной активностью в отношении боли
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
SG11201906164RA (en) 2017-01-11 2019-08-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
JP2022512367A (ja) 2018-12-12 2022-02-03 ケモセントリックス，インコーポレイティド 癌治療のためのｃｘｃｒ７阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114334A (en) * 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
US6727264B1 (en) * 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
GB0228417D0 (en) * 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
WO2005019182A1 (en) * 2003-08-20 2005-03-03 Bayer Healthcare Ag Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists

Also Published As

Publication number Publication date
AU2007275049A1 (en) 2008-01-24
AU2007275049B2 (en) 2011-03-03
BRPI0714440A2 (pt) 2013-04-24
CL2007002123A1 (es) 2008-06-13
AR062011A1 (es) 2008-08-10
KR20090029274A (ko) 2009-03-20
RU2425826C2 (ru) 2011-08-10
US20090306039A1 (en) 2009-12-10
MX2009000771A (es) 2009-01-30
RU2009105829A (ru) 2010-08-27
WO2008011611A3 (en) 2008-05-02
JP2009544626A (ja) 2009-12-17
EP2057124A2 (en) 2009-05-13
CA2656715A1 (en) 2008-01-24
TW200817375A (en) 2008-04-16
WO2008011611A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
TW200738655A (en) Novel bicyclic sulfonamide derivatives
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20080401A1 (es) DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
PE20090241A1 (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
PE20090775A1 (es) Nuevos derivados de biarilo
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
PE20080281A1 (es) COMPUESTOS CINAMIDA COMO INHIBIDORES DE LA SINTESIS DEL ß-AMILOIDE 40 Y 42
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20100087A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1

Legal Events

Date Code Title Description
FC Refusal